top of page

Align Summit 2026: Calluna Pharma has a S100A4 (a DAMP) targeting program currently in phase 2 for IPF that will read out in Q1 2027

6 hours ago
1 min read

CEO Mark Gaffney walks us through the idea of targeting a DAMP and, in this case, S100A4 specifically, and describes the differentiated profile Calluna hopes to see compared to currently marketed therapies for IPF.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page